{
  "date": "2026-01-18",
  "generated_at": "2026-01-18T22:11:28.580555",
  "theme": "minimal",
  "total_items": 38,
  "files": {
    "markdown": "/Users/kid/priv/pharma-daily/docs/20260118/daily.md",
    "html": "/Users/kid/priv/pharma-daily/docs/20260118/index.html",
    "directory": "/Users/kid/priv/pharma-daily/docs/20260118"
  },
  "analysis": {
    "overview": "今日制药行业动态聚焦于监管政策调整与重磅药物市场表现。FDA正调整一期临床试验规定以应对中国生物技术崛起，同时加速审批项目面临企业担忧；GLP-1药物市场持续火热，诺和诺德口服版Wegovy上市首周处方量超3000份，显示减肥药领域竞争白热化。",
    "top_news": [
      {
        "index": 1,
        "title": "Makary talks FDA's plans to combat China's biotech growth",
        "importance": 5,
        "reason": "FDA局长明确表态将调整一期试验规定以应对中国生物技术崛起，反映全球生物医药竞争格局变化",
        "category": "政策法规"
      },
      {
        "index": 3,
        "title": "Wegovy pill off to a fast start; Ex-Emergent CEO sued for insider trading",
        "importance": 5,
        "reason": "诺和诺德口服GLP-1药物上市首周处方量超3000份，显示减肥药市场进入新剂型竞争阶段",
        "category": "市场分析"
      },
      {
        "index": 21,
        "title": "AbbVie, Genmab say Epkinly didn't prolong overall survival in lymphoma study",
        "importance": 4,
        "reason": "艾伯维与Genmab的淋巴瘤药物三期试验未达到总生存期终点，影响该产品市场前景",
        "category": "临床试验"
      },
      {
        "index": 8,
        "title": "STAT+: Pharmalittle: We’re reading about FDA voucher worries, weight loss drugs and jet fuel, and more",
        "importance": 4,
        "reason": "大型药企因法律风险对FDA加速审批项目持谨慎态度，反映监管政策执行面临挑战",
        "category": "监管审批"
      },
      {
        "index": 30,
        "title": "#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026",
        "importance": 4,
        "reason": "山德士CEO在JPM大会上透露2026年推出Ozempic仿制药计划，将冲击GLP-1药物市场格局",
        "category": "商业动态"
      }
    ],
    "category_summary": {
      "新药研发": "Exelixis凭借单一药物Cabometyx瞄准美国实体瘤前五地位；ImmunityBio的现货型细胞疗法在罕见血癌早期试验中显示潜力；Agomab与SpyGlass提交IPO申请，显示投资者对生物技术领域热情回升",
      "临床试验": "艾伯维/Genmab的Epkinly在弥漫性大B细胞淋巴瘤三期试验中未改善总生存期；FDA加速审批项目中部分癌症药物已验证临床获益；EMA在2025年推荐38种新药，比FDA少15种"
    },
    "tomorrow_watch": "需关注FDA对一期试验规定的具体调整方案及其对中美生物技术竞争的影响；山德士GLP-1仿制药具体上市时间表及定价策略；最高法院将审理Hikma与Amarin的'瘦身标签'诉讼案，结果可能影响仿制药标签法规"
  }
}